Kymazol

Simvastatin, the active ingredient in Kymazol, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It treats elevated cholesterol and triglyceride levels and helps reduce cardiovascular risk in adults with hypercholesterolemia or related conditions.

GNH USA supplies Kymazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kymazol (simvastatin) acts on lipid metabolism pathways to lower abnormal blood lipids. - Hypercholesterolemia: reduces total and LDL cholesterol levels. - Hyperlipidemia: lowers triglycerides and improves overall lipid profile. - Cardiovascular risk reduction: decreases the incidence of myocardial infarction and stroke in patients at elevated risk.

Simvastatin may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Gastrointestinal upset: includes nausea, abdominal discomfort or diarrhoea. - Myalgia: muscle aches or soreness without weakness. - Elevated liver enzymes: mild increases in ALT or AST. - Dizziness: transient light‑headedness or vertigo.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Myopathy: muscle weakness with elevated creatine kinase. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, several safety considerations are recommended. - Liver function monitoring: assess baseline transaminases and repeat periodically. - Muscle symptom assessment: evaluate for unexplained muscle pain, tenderness or weakness. - Drug interaction review: check for concomitant use of strong CYP3A4 inhibitors. - Pregnancy avoidance: contraindicated in pregnancy (Category X). - Dose adjustment in renal impairment: consider lower doses in patients with severe renal dysfunction. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Simvastatin may interact with other medicines, requiring caution.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors): can markedly increase simvastatin levels. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Danazol: enhances simvastatin exposure and muscle toxicity. - Cyclosporine: increases plasma concentrations, heightening adverse effect risk.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly raise simvastatin concentrations. - Diltiazem: can increase risk of muscle-related side effects. - Grapefruit juice: may elevate simvastatin levels, requiring dose adjustment.